Kezdőlap・Részvénylista・ADMA Biologics Inc

ADMA Biologics Inc

Nyitva

SzektorEgészségügy

9.4 -3.79

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

9.59

Maximum

9.94

Fő mutatók
By Trading Economics
Bevétel	-7.5M 38M
Értékesítés	9.9M 124M
P/E Szektor átlag	13.929 57.002
Egy részvényre jutó nyereség	0.16
Profit margin	30.405
Munkavállalók	640
EBITDA	-3.8M 57M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+73.82% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 4.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	158M 2.2B
Előző nyitás	13.19
Előző zárás	9.4

Hangulat hírek alapján

By Acuity

100%

323 / 340 Rangsor szerint Healthcare

ADMA Biologics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 12. 19:46 UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

2026. aug. 11. 22:56 UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

2026. aug. 7. 19:46 UTC

Correlated Moves

News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

2026. aug. 6. 20:02 UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

2026. aug. 5. 23:02 UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

2026. aug. 4. 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

2026. aug. 3. 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

2026. júl. 31. 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

2026. júl. 30. 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

2026. júl. 29. 18:17 UTC

News

Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

2026. júl. 28. 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

2026. júl. 27. 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

2026. júl. 24. 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

2026. júl. 22. 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

2026. júl. 21. 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

2026. júl. 20. 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Társak összehasonlítása

Árváltozás

ADMA Biologics Inc Előrejelzés

Célár

By TipRanks

73.82% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 17 USD 73.82%

Magas 21 USD

Alacsony 12 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)ADMA Biologics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

4 ratings

Vétel

Tartás

Eladás

4 Wall Street elemző célárain alapulva a(z)ADMA Biologics Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

323 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.